US4990519A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1990-02-23
•
Granted: 1991-02-05
•
Expires: 2010-02-23
Abstract
Abstract This invention relates to novel quinolyloxazole-2-ones which are useful as protein kinase C inhibitors, effective in the treatment of hypertension and asthma. This invention also includes a novel procedure for producing an intermediate ketone compound involving the reaction of a bromo-quinoline compound with butyl lithium and further reacting the lithiated compound with N-methyl-N-methoxyalkanamide.
Inventors
- 👤 Winton D. Jones
- 👤 George P. Claxton
- 👤 Richard C. Dage
- 👤 Hsien C. Cheng
- 👤 Phillip J. Robinson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 20:17
CPC Classifications
C; C07; C07D; C07D413/00; C07D413/02; C07D413/04
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
151 words
A method of treating asthma which comprises administering to a patient in need thereof a compound of the formula ##STR5## wherein R and R 1 are each independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 3 alkylphenyl wherein the phenyl ring is optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy nitro and trifluoromethyl; and R 2 is a 2-, 3-, or 4-quinolyl group optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy, nitro and trifluoromethyl; or R 2 is a 5-, 6-, 7-, or 8-quinolyl group; or a pharmaceutically-acceptable salt thereof, in an amount necessary to effect a bronchodilatory result.
Claim 2
Independent Claim
151 words
A method of treating asthma which comprises administering to a patient in need thereof a compound of the formula ##STR5## wherein R and R 1 are each independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 3 alkylphenyl wherein the phenyl ring is optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy nitro and trifluoromethyl; and R 2 is a 2-, 3-, or 4-quinolyl group optionally substituted with one, two or three of the substituents selected from the group consisting of fluorine, chlorine, bromine, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy, nitro and trifluoromethyl; or R 2 is a 5-, 6-, 7-, or 8-quinolyl group; or a pharmaceutically-acceptable salt thereof, in an amount necessary to effect a bronchodilatory result.
Claim 3
Dependent Claim
28 words
A method of producing a bronchodilatory effect, in a patient in need thereof through the administration of a pharmaceutically-effective amount of a compound of claim 1, Formula 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-04 | 1994-08-06 | 1995-02-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-04 | 1998-08-06 | 1999-02-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-04 | 2002-08-06 | 2003-02-05 | $7700.00 | Window Closed / Lapsed |